Neurogenesis, Inc. Stock

Equities

Market Closed - OTC Markets Other stock markets 02:49:23 2024-06-12 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	0.00%

2023	Neurogenesis, Inc. Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome	CI
2021	Neurogene Inc. and University of Edinburgh Announces Research Collaboration to Advance Next Generation Gene Therapies	CI

Duration

Period

Style

Neurogenesis, Inc. Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome	Nov. 30	CI
Neurogene Inc. and University of Edinburgh Announces Research Collaboration to Advance Next Generation Gene Therapies	21-01-19	CI
Hadassah Medical Center and Neurogenesis Announce Results from a Phase 2 Study in Progressive Multiple Sclerosis treated with NG-01 Autologous Cells Therapy	20-12-08	CI
Neurogene Names Kenneth Huttner as Senior VP of Clinical Development	20-07-26	CI